To ask the Secretary of State for Health whether the National Cancer Director's forthcoming review of cancer drugs will evaluate geographical variations in the use of cancer drugs (a) approved by and (b) awaiting appraisal by the National Institute for Health and Clinical Excellence. (186269)

The National Cancer Director's forthcoming review of cancer drugs will evaluate the usage of National Institute of Health and Clinical Excellence (NICE)-approved cancer drugs. It will not evaluate the usage of cancer drugs awaiting appraisal by NICE.

It is expected that the evaluation report will be published before the end of the year.